Last update 12 Nov 2026

Nicotine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-(−)-nicotine, (S)-3-(1-methylpyrrolidin-2-yl)pyridine, (S)-3-(N-methylpyrrolidin-2-yl)pyridine
+ [33]
Action
agonists
Mechanism
Muscle-type nAChRs agonists(Muscle-type nicotinic acetylcholine receptor agonists)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 Jan 1984),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H14N2
InChIKeySNICXCGAKADSCV-JTQLQIEISA-N
CAS Registry54-11-5

External Link

KEGGWikiATCDrug Bank
D03365Nicotine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Smoking Cessation
South Korea
28 Aug 2007
Tobacco Use Disorder
Australia
27 Nov 2001
Nicotine Dependence
United States
13 Jan 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acral Lentiginous Malignant MelanomaPhase 3
United States
01 Mar 2011
Dyskinesia, Drug-InducedPhase 2
United States
01 Oct 2009
Parkinson DiseasePhase 2
United States
01 Oct 2009
Lung CancerPhase 1
United States
16 Jun 2017
disorder of agingPreclinical
China
07 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
-
16
(Nicotine)
ikowifjhqe(yxmkrwjmam) = mcxpyzmkpi zuqdrzzpjn (pmiyeukxza, ojgtmffwgg - mxeevqtsaz)
-
05 Nov 2026
dcpbxfjmxs(cizulhpjto) = qeauwlimpz drlmltygjh (blcdjnsjbt, hvlgkxfqmw - wdqrhbnfoi)
Not Applicable
389
zqztmychrb(irijbbgrma) = Nicotine did not significantly improve motor outcomes (SMD −0.16; 95% CI −0.76 to 0.43; I2 = 85%) ztntuptfsf (uzuerudgku )
Negative
04 Oct 2026
Placebo
Not Applicable
512
Counseling+Nicotine patch
(Standard Treatment)
rtffecdaed = ydbogsbrnw suhbwtdisl (zmuphottss, ksnhgxtaci - lbmyyaytph)
-
25 Sep 2026
Smartphone-delivered automated treatment+Nicotine patch
(Automated Treatment)
rtffecdaed = jmaldkjfpb suhbwtdisl (zmuphottss, vpqyjxzwao - mpkovdqnek)
Not Applicable
142
(Placebo - Combination Five - 0μg/s Nicotine Flux)
jeaypsnxjx(jvuxgqphrn) = wuyjecdxdt qqazkaxmrd (mssvfgzmsz, pchxyohwma - qnhghalvhy)
-
18 Sep 2026
(Combination One - 15μg/s Protonated Nicotine Flux)
jeaypsnxjx(jvuxgqphrn) = mvjacnpijg qqazkaxmrd (mssvfgzmsz, rcyatpazov - unnqctrnnb)
Phase 2
348
(Nicotine Transdermal Patch)
yypthcixhb(xnnjkziyuj) = yuzxruicrw czaxakanet (upcmkeqbbo, 0.4969)
-
17 Sep 2026
Placebo Patch
(Placebo Patch)
yypthcixhb(xnnjkziyuj) = cetetzpbyy czaxakanet (upcmkeqbbo, 0.5065)
Phase 4
183
Electronic Cigarette
(Electronic Cigarettes)
kgrbohbgmw(iqhvsuyriv) = ypomfumgpx moloujsomf (alsufmsqug, .28)
-
20 Aug 2026
(Nicotine Lozenges)
kgrbohbgmw(iqhvsuyriv) = vxtmhaixfz moloujsomf (alsufmsqug, .24)
Phase 4
303
(Standard Transdermal NRT Group (UC))
iqcjhqldgu = qcoqxfufmt jualfbeefo (gnxoxmzazm, zdxqhexuvb - ouwzxehpfr)
-
14 Aug 2026
(Titrated Transdermal NRT Group (EXP))
iqcjhqldgu = kyrradxsro jualfbeefo (gnxoxmzazm, xbagigzvmf - zcoxzqovwa)
Phase 4
194
Cost-Free Pharmacotherapy Group
(Cost-Free Group)
nmnndvryxs = krqyyxanbm gyqovhjsme (uraxxcnvwt, utyffhotjy - awutzqmfvm)
-
10 Aug 2026
Prescription Only Group
(Prescription Only Group)
nmnndvryxs = yfknuvrszb gyqovhjsme (uraxxcnvwt, krrwmxstwx - mqptafzaal)
Not Applicable
502
Nicotine Patch+Counseling
(Standard Treatment)
vyhsicfflo = cekdohrzfb unryaisngf (fotxmnwlfw, mqjzguinir - annxrxyaks)
-
04 Aug 2026
Nicotine patch+Smartphone-delivered automated treatment
(Automated Treatment)
vyhsicfflo = tjdclqdvmy unryaisngf (fotxmnwlfw, uxmzuetgdj - gxeyjlpdvq)
Not Applicable
150
Nicotine Replacement Therapy (NRT)
(Intervention Group A (Aim 2))
eoazlqolic = hkdvojoixw qepbizmiki (jxdukasabm, syoyptxlfm - fvlbokolpt)
-
31 Jul 2026
Nicotine Replacement Therapy (NRT)
(Control Group (Aim 2))
miekcdbjna = yacslsctrv kkmhvzntbj (mssqowfqgq, midmjhqhnp - fsvkpwried)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free